NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.250
+0.020 (1.63%)
At close: Nov 5, 2024, 4:00 PM
1.320
+0.070 (5.60%)
After-hours: Nov 5, 2024, 6:05 PM EST
NeuroSense Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 5, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 24 | 11 | 14 | 26 | - | - |
| Market Cap Growth | 3.26% | -24.68% | -46.24% | - | - | - |
| Enterprise Value | 23 | 6 | 6 | 25 | - | - |
| Last Close Price | 1.23 | 0.79 | 1.22 | 2.46 | - | - |
| PE Ratio | - | -1.06 | -1.34 | -4.77 | - | - |
| PB Ratio | -11.86 | -6.10 | 2.44 | 2.94 | - | - |
| P/FCF Ratio | -1.98 | -1.28 | -1.85 | -17.02 | - | - |
| P/OCF Ratio | -1.98 | -1.28 | -1.87 | -17.21 | - | - |
| EV/EBITDA Ratio | -1.67 | -0.50 | -0.57 | -8.55 | - | - |
| EV/EBIT Ratio | -1.67 | -0.50 | -0.57 | -8.54 | - | - |
| EV/FCF Ratio | -1.91 | -0.72 | -0.78 | -16.39 | - | - |
| Debt / Equity Ratio | -0.02 | -0.08 | 0.04 | - | - | - |
| Debt / FCF Ratio | 0.00 | -0.02 | -0.03 | - | - | - |
| Quick Ratio | 0.45 | 0.81 | 4.18 | 18.83 | 6.08 | 24.68 |
| Current Ratio | 0.46 | 0.84 | 4.28 | 19.12 | 6.38 | 24.68 |
| Return on Equity (ROE) | - | -494.83% | -141.31% | -66.63% | -358.66% | - |
| Return on Assets (ROA) | -150.79% | -138.15% | -68.90% | -30.56% | -208.19% | - |
| Return on Capital (ROIC) | - | -339.37% | -87.59% | -38.61% | -228.92% | - |
| Earnings Yield | -40.91% | -94.21% | -73.67% | -12.16% | - | - |
| FCF Yield | -42.62% | -78.14% | -53.97% | -5.87% | - | - |
| Buyback Yield / Dilution | -36.48% | -18.56% | -84.27% | -13.12% | -19.10% | - |
| Total Shareholder Return | -36.48% | -18.56% | -84.27% | -13.12% | -19.10% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.